Nimesulide ban: Govt bars sale of oral painkiller doses above 100 mg
The government has barred the manufacture and sale of oral nimesulide formulations above 100 mg, saying higher doses carry health risks and safer options are available.
The government has barred the manufacture and sale of oral nimesulide formulations above 100 mg, saying higher doses carry health risks and safer options are available.
The Union Health Ministry, in partnership with the World Health Organisation, rolled out a month-long Delhi Metro campaign on women’s and girls’ health and well-being at the Sultanpur Metro Station here on Wednesday.
The facilities will be open to the public from November 14 until the close of the 44th India International Trade Fair (IITF) in New Delhi on November 27.
During the meeting, participants deliberated on policy priorities such as equitable workforce distribution, quality assurance in education and training institutions, leadership development, and career progression opportunities for nursing professionals.
She urged mass public participation for the ongoing nationwide awareness drive until October 17, stating that nearly 70 percent of deaths due to heart failure occur outside the hospital settings — where immediate medical assistance is often unavailable.
In a communiqué, the Health Ministry said, “The first meeting of the NTF set up in accordance with directions of the Supreme Court was held today under the chairmanship of the Cabinet Secretary. All members including the Home Secretary and Health Secretary were present at the meeting.”
The panel which will be headed by Cabinet Secretary, Government of India as its Chairperson has been constituted following the Supreme Court's direction on 20th August.
The Health Ministry said the primary objectives of the project include developing standard protocols for micro/nano-plastic analysis, conducting intra- and inter-laboratory comparisons, and generating critical data on microplastic exposure levels among consumers.
It is important that proactive measures be taken to prevent violence against healthcare professionals/staff, read the advisory.
This landmark trial will evaluate the efficacy of India’s indigenous tetravalent dengue vaccine, DengiAll, developed by Panacea Biotec, it said.
